The content of this website is intended for United States audiences only.
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) (EVOKE-SCLC-04)
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on objective response rate (ORR) as assessed by blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors and to compare the effect of SG to SOC on overall survival (OS).
View MoreAge
18 Years +
Sex
ALL
Healthy Volunteers
No
Medical Condition
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Gender
N/A
Date
April 2025 - October 2029
Study Type
INTERVENTIONAL
Study Phase
PHASE3
Product
Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only)
Hinsdale, Illinois, United States, 60521
Springfield, Illinois, United States, 62702
Springfield, Illinois, United States, 62702
Fort Wayne, Indiana, United States, 46845
Muncie, Indiana, United States, 47303
Dyer, Kentucky, United States, 46311
Sandusky, Ohio, United States, 44870
Toledo, Ohio, United States, 43617
Easton, Pennsylvania, United States, 18045
Abilene, Texas, United States, 79601
Houston, Texas, United States, 77030
Tyler, Texas, United States, 75708
New South Wales, New South Wales, Australia, 2500
Queensland, Queensland, Australia, 4006
Southport, Queensland, Australia, 4215
Adelaide, South Australia, Australia, 5000
Fitzroy, Victoria, Australia, 3065
Nedlands, Western Australia, Australia, 6009
Montreal, Canada, H4A 3J1
Changchun, China, 130012
Chengdu, China, 610041
Chongqing, China, 404100
Guangzhou, China, 130012
Hangzhou, China, 310016
Harbin, China, 150081
Jiangxi, China, 330008
Kunming, China, 650000
Linyi, China, 276000
Shanghai, China
Tianjin, China, 300181
Weifang, China, 261041
Wuhan, China, 430030
Angers, France, 49933
Créteil, France, 94000
Paris, France, 75248
Pessac, France, 33604
Hamburg, Germany, 22087
Minden, Germany, 32429
Beersheba, Israel, 84001
Haifa, Israel, 3109601
Jerusalem, Israel, 9112001
Kfar Saba, Israel, 44281
Naharyia, Israel, 11111
Aviano, Italy, 33081
Naples, Italy, 80131
Naples, Italy, 80131
Peschiera del Garda, Italy, 37019
Roma, Italy, 144
Roma, Italy, 168
Fukuoka, Japan, 812-8582
Fukuoka, Japan, 830-0011
Hyōgo, Japan, 673-8558
Kanagawa, Japan, 241-0815
Kobe, Japan, 650-0047
Miyagi, Japan, 981-0914
Okayama, Japan, 700-8558
Osaka, Japan, 534-0021
Osaka, Japan, 573-1191
Osaka, Japan, 591-8555
Saitama, Japan, 362-0806
Tokyo, Japan, 113-8603
Tokyo, Japan, 135-8550
Kuala Lumpur, Malaysia, 59100
Kuala Selangor, Malaysia, 46050
Kuala Selangor, Malaysia, 47500
Kuching, Malaysia, 93586
Lembah Pantai, Malaysia, 59100
Amsterdam, Netherlands, 1081 HV
Utrecht, Netherlands, 3543 AZ
Lodz, Poland, 90-302
Poznan, Poland, 60-693
Rzeszów, Poland, 35-055
Siedlce, Poland, 08-110
Stupsk, Poland, 076-200
Changwon-Si, South Korea
Gwangju, South Korea, 61469
Seongbuk-Gu, South Korea
Seongnam, South Korea, 13620
Seoul, South Korea, 03181
Seoul, South Korea, 05505
Seoul, South Korea, 06351
Seoul, South Korea, 06591
Seoul, South Korea, 120-752
Seoul, South Korea, 52727
Suwon, South Korea, 16247
Ulsan, South Korea, 44033
A Coruña, Spain, 15006
Barcelona, Spain, 08036
Barcelona, Spain, 08041
Girona, Spain, 17007
Jaén, Spain, 23007
Madrid, Spain, 28041
Seville, Spain, 41013
Seville, Spain, 41014
Valencia, Spain, 46010
Changhua, Taiwan, 500-06
Kaohsiung City, Taiwan, 80756
Taichung, Taiwan, 40705
Tainan City, Taiwan, 704
Taipei, Taiwan, 10002
Taipei, Taiwan, 100
Taipei, Taiwan, 112
Taoyuan, Taiwan, 33305
Share Trial